Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors

Introduction

-
-
-

Conclusions

Introduction

-

-

Results

GFS784 is a novel EGFR-targeted ADC equipped with a pan-RAS(ON) inhibitor payload.